Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: A longitudinal study

Annals of Oncology

Volumn 22, Issue 8, 2011, Pages 1916-1921

  Toriola, A T ^a,b   Grankvist, K ^c   Agborsangaya, C B ^b   Lukanova, A ^d   Lehtinen, M ^b   Surcel, H M ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c UMEÅ UNIVERSITY   (Sweden)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Biobanks; C reactive protein; Inflammation; Longitudinal study; Ovarian cancer; Prospective study

Indexed keywords

C REACTIVE PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; FINLAND; HIGH RISK POPULATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OVARY CANCER; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR;

EID: 79961005817     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq694     Document Type: Article

References (28)

1. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999; 91: 1459-1467.
2. Langseth H, Hankinson SE, Siemiatycki J, Weiderpass E. Perineal use of talc and the risk of ovarian cancer. J Epidemiol Community Health 2008; 62: 358-360.
3. Brinton LA, Gridley G, Persson I et al. Cancer risk after a hospital discharge of endometriosis. Am J Obstet Gynecol 1997; 176: 572-579.
4. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1995; 4: 447-451.
5. Ness RB, Grisso JA, Cottreau C et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000; 11(2): 111-117.
6. Shan W, Liu J. Inflammation; a hidden path to breaking the spell of ovarian cancer. Cell Cycle 2009; 8(19): 3107-3111.
7. Green A, Purdie D, Bain C et al. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group. Int J Cancer 1997; 71: 948-951.
8. Schildkraut JM, Moorman PG, Halabi S et al. Analgesic use and the risk of ovarian cancer. Epidemiology 2006; 17: 104-107.
9. Wernli KJ, Newcomb PA, Hampton JM et al. Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer 2008; 98: 1781-1783.
10. Gertig DM, Hunter DJ, Cramer DW et al. Prospective study of talc use and ovarian cancer. J Natl Cancer Inst 2000; 92: 249-252.
11. Merritt MA, Green AC, Nagle CM, Webb PM. Australian Cancer Study (Ovarian cancer) and Australian Ovarian Cancer Study Group. Int J Cancer 2008; 122: 170-176.
12. Bonovas S, Filioussi K, Sitaras MN. Do non-steroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol 2005; 60(2): 194-203.
13. Pinhiero PS, Tworoger SS, Cramer DW et al. Use of non-steroidal anti-inflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol 2009; 169: 1378-1387.
14. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-137.
15. McSorley MA, Alberg AJ, Allen DS et al. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 2007; 109(4): 933-941.
16. Lundin E, Dossus L, Clendenen T et al. C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy). Cancer Causes Control 2009; 20(7): 1151-1159.
17. Ockene IS, Matthews CE, Rifai N et al. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001; 47(3): 444-450.
18. Koskela P, Anttila T, Bjørge T et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 2000; 85: 35-39.
19. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994; 33: 365-369.
20. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practices. Circulation 2003; 107: 499-511.
21. Alley DE, Crimmins E, Bandeen-Roche K et al. Three-year change in inflammatory markers in elderly people and mortality: the Invecchiare in Chianti study. J Am Geriatr Soc 2007; 55(11): 1801-1807.
22. Fleming JS, Beaugie CR, Haviv I et al. Incessant ovulation, inflammation and epithelial ovarian cancer: revisiting old hypothesis. Mol Cell Endocrinol 2006; 247: 4-21.
23. Epsey LL. Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. Biol Reprod 1994; 50: 233-238.
24. Bonello N, Mckie K, Jasper M et al. Inhibition of nitric oxide: effects on interleukin-1 beta-enhanced ovulation rate, steroid hormones, and ovarian leukocyte distribution at ovulation in the rat. Biol Reprod 1996; 54: 436-445.
25. Ames BN, Gold LS, Willet WC. The causes and prevention of cancer. Proc Natl Acad Sci U S A 1995; 92: 5258-5265.
26. Mantovani A, Allavena P, Sica A, Balkwill S. Cancer-related inflammation. Nature 2008; 454: 436-444.
27. Mills PK, Riordan DG, Cress RD, Young HA. Perineal talc exposure and epithelial ovarian cancer risk in the central valley of California. Int J Cancer 2009; 112: 458-464.
28. Wu AH, Pearce CL, Tseng C-C et al. Markers of inflammation and the risk of ovarian cancer in Los Angeles County. Int J Cancer 2009; 124: 1409-1415.